Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 3.1.1 EX-3.1.1
- 3.1.2 EX-3.1.2
- 3.1.3 EX-3.1.3
- 3.1.4 EX-3.1.4
- 3.1.5 EX-3.1.5
- 3.1.6 EX-3.1.6
- 3.2.1 EX-3.2.1
- 3.2.2 EX-3.2.2
- 3.2.3 EX-3.2.3
- 3.2.4 EX-3.2.4
- 3.2.5 EX-3.2.5
- 3.2.6 EX-3.2.6
- 4.1 EX-4.1
- 4.2 EX-4.2
- 4.4 EX-4.4
- 4.5 EX-4.5
- 5.1 EX-5.1
- 5.2 EX-5.2
- 10.11 EX-10.11
- 10.12 EX-10.12
- 10.13 EX-10.13
- 10.14 EX-10.14
- 10.15 EX-10.15
- 10.16 EX-10.16
- 10.17 EX-10.17
- 10.18 EX-10.18
- 10.19 EX-10.19
- 10.20 EX-10.20
- 10.21 EX-10.21
- 10.22 EX-10.22
- 10.23 EX-10.23
- 10.24 EX-10.24
- 10.25 EX-10.25
- 10.26 EX-10.26
- 10.27 EX-10.27
- 12 EX-12
- 16 EX-16
- 21 EX-21
- 23.1 EX-23.1
- 25.1 EX-25.1
- 99.1 EX-99.1
- 99.2 EX-99.2
- 99.3 EX-99.3
- 99.4 EX-99.4
Filing view
External links
Exhibit 16
August 14, 2013
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7561
Dear Sirs/Madams:
We have read the Change in Auditors disclosure of Par Pharmaceutical Companies, Inc. Form S-4 dated August 14, 2013, and have the following comments:
| 1. | We agree with the statements made in the 2nd and 3rd paragraphs. |
| 2. | We have no basis on which to agree or disagree with the statements made in the 1st and 4th paragraphs. |
Yours truly,
/s/ DELOITTE & TOUCHE LLP
New York, New York